問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

List

1457Cases

2018-11-01 - 2019-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate to Severe Atopic Dermatitis BREEZE-AD7

  • Condition/Disease

    Moderate to Severe Atopic Dermatitis

  • Test Drug

    Baricitinib (LY3009104)

Participate Sites
5Sites

Terminated5Sites

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2022-12-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-07-31 - 2026-05-27

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2023-07-03 - 2028-07-26

Phase III

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)

  • Condition/Disease

    Obesity 、Overweight、 Overweight or Obesity

  • Test Drug

    LY3502970

Participate Sites
5Sites

Recruiting5Sites

2023-04-01 - 2025-12-31

Phase I/II

A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors

  • Condition/Disease

    Malignant Solid Tumor

  • Test Drug

    Gen1042

Participate Sites
7Sites

Recruiting7Sites

2021-11-01 - 2026-08-02

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2022-06-01 - 2022-08-19

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2021-11-01 - 2026-02-28

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting3Sites

Terminated2Sites

2023-11-01 - 2028-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2023-07-31 - 2026-04-30

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

1 123 124 125 126 127 146
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB